Treatment of Obesity in 2015

Journal of Cardiopulmonary Rehabilitation and Prevention

Volumn 35, Issue 2, 2015, Pages 81-92

  Shukla, Alpana P ^a   Buniak, William I ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bariatric surgery; lifestyle interventions; obesity; pharmacotherapy

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; DRUG COMBINATION; FRUCTOSE; LACTONE; TOPIRAMATE;

BEHAVIOR THERAPY; COMORBIDITY; DIET; DRUG THERAPY; ENERGY BALANCE; ENERGY EXPENDITURE; GASTRIC BANDING; HUMAN; LAPAROSCOPIC SLEEVE GASTRECTOMY; LAPAROSCOPIC SURGERY; LIFESTYLE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; ROUX EN Y GASTRIC BYPASS; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BARIATRIC SURGERY; CALORIC RESTRICTION; DRUG COMBINATION; EXERCISE; FEEDING BEHAVIOR; RISK REDUCTION;

ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BENZAZEPINES; CALORIC RESTRICTION; DRUG COMBINATIONS; EXERCISE; FOOD HABITS; FRUCTOSE; HUMANS; LACTONES; OBESITY; PHENTERMINE; RISK REDUCTION BEHAVIOR;

EID: 84947320432     PISSN: 19327501     EISSN: 1932751X     Source Type: Journal    
DOI: 10.1097/HCR.0000000000000112     Document Type: Review

References (90)

1. Finucance MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systemic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377 (9765): 557-567.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307: 491-497.
3. Centers for Disease Prevention and Prevention. Overweight and obesity. Adult Obes Facts. 2014. http://www.cdc.gov/obesity/data/adult.html. Accessed April 21, 2014.
4. Jackson JE, Doescher MP, Saver BG, Hart LG. Trends in professional advice to lose weight among obese adults, 1994-2000. J Gen Intern Med. 2005; 20: 814-818.
5. Haire-Joshu D, Klein S. Is primary care practice equipped to deal with obesity? [Comment]. Arch Intern Med. 2011; 171: 313-315.
6. Kushner RF. Tackling obesity: is primary care up to the challenge . Arch Intern Med. 2010; 170: 121-123.
7. Aronne LJ, Nelinson DS, Lillo JL. Obesity as a disease state: a new paradigm for diagnosis and treatment. Clin Cornerstone. 2009; 9: 9-25.
8. Ford ES, Dietz WH. Trends in energy intake among adults in the United States: findings from NHANES. Am J Clin Nutr. 2013; 97: 848-853.
9. Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One. 2011; 6: e19657.
10. Ladabaum U, Mannalithara A, Myer PA, Singh G. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010. Am J Med. 2014; 127: 717-727.
11. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guidelines for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2985-3025.
12. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013; 1: 93-102.
13. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol. 2014; 63: 1345-1354.
14. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009; 53: 1925-1932.
15. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008; 156: 13-22.
16. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity . Epidemiology. 2014; 25: 454-461.
17. McAuley PA, Artero EG, Sui X, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012; 87: 443-451.
18. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-1350.
19. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
20. Ades PA, Savage PD. Potential benefits of weight loss in coronary heart disease. Prog Cardiovasc Dis. 2014; 56: 448-456.
21. Aucott L, Gray D, Rothnie H, Thapa M, Waweru C. Effects of lifestyle interventions and long-term weight loss on lipid outcomes-a systematic review. Obes Rev. 2011; 12: e412-e425.
22. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992; 56: 320-328.
23. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001; 9: 326S-334S.
24. Ades PA, Savage PD, Toth MJ, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation. 2009; 119: 2671-2678.
25. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil. 2008; 15: 336-340.
26. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO. The obesity paradox, weight loss, and coronary disease. Am J Med. 2009; 122: 1106-1114.
27. Igel LI, Powell AG, Apovian CM, Aronne LJ. Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. Curr Atheroscler Rep. 2012; 14: 60-69.
28. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009; 360: 481-490.
29. Georgiades A, Sherwood A, Gullette ECD, et al. Effects of exercise and weight loss on mental stress-induced cardiovascular responses in individuals with high blood pressure. Hypertension. 2000; 36: 171-176.
30. Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci. 2002; 967: 379-388.
31. Ravussin E, Bogardus C. Energy balance and weight regulation: genetics versus environment. Br J Nutr. 2000; 83: S17-S20.
32. Liebel R, Rosenbaum M. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995; 332: 621-628.
33. Brehm BJ, Seeley RJ, Daniels SR, D'Alession DA. A randomized trial comparing a very low carbohydrate diet and a calorierestricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003; 88: 1617-1623.
34. Due A, Larsen TM, Mu H, Hermanseb K, Stender S, Astrup A. Comparison of 2 ad libitum diets for weight-loss maintenance, risk of cardiovascular disease and diabetes: a 6-mo randomized, controlled trial. Am J Clin Nutr. 2008; 88: 1232-1241.
35. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet. Ann Intern Med. 2010; 153: 147-157.
36. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008; 359: 229-241.
37. Harvery-Berino J. Calorie restriction is more effective for obesity treatment than dietary fat restriction. Ann Behav Med. 1999; 21: 35-39.
38. Tanumihardjo SA, Valentine AR, Zhang Z, Wingham LD, Lai HJ, Atkinson RL. Strategies to increase vegetable or reduce energy and fat intake induce weight loss in adults. Exp Biol Med. 2009; 234: 542-552.
39. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different composition of fat, protein, and carbohydrate . N Engl J Med. 2009; 360: 859-873.
40. Blomain ES, Dirhan DA, Valentino MA, Kim GW, Waldman SA. Mechanisms of weight regain following weight loss. ISRN Obes. 2013; 2013: 210524. doi: 10.1155/2013/210524.
41. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome ? Am J Clin Nutr. 2003; 78: 684-689.
42. Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr. 1997; 66: 239-246.
43. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine Position Stand: appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009; 41: 459-471.
44. Hunter GR, Byrne NM, Sirikul B, et al. Resistance training conserves fat-free mass and resting energy expenditure following weight loss. Obesity (Silver Spring). 2012; 16: 1045-1051.
45. Pasman WJ, Saris WHM, Muls E, Vansant G, Westerterp-Plantenga MS. Effect of exercise training on long-term weight maintenance in weight-reduced men. Metabolism. 1999; 48: 15-21.
46. Danielsen KK, Svendsen M, Mæhlum S, Sungot-Borgen J. Changes in body composition, cardiovascular disease risk factors, and eating behavior after intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. J Obes. 2013; 2013: 325464. doi: 10.1155/2013/325464.
47. Lowe MR, Tappe KA, Annunziato RA, et al. The effect of training in reduced energy density eating and food self-monitoring accuracy on weight loss maintenance. Obesity. 2008; 16: 2016-2023.
48. Butryn ML, Phelan S, Hill JO, Wing RR. Consistent selfmonitoring of weight: a key component of successful weight loss maintenance. Obesity. 2007; 15: 3091-3096.
49. Ades PA, Savage PD, Lischke S, et al. The effect of weight loss and exercise training on flow-mediated dilatation in coronary heart disease: a randomized trial. Chest. 2011; 140: 1420-1427.
50. Pedersen LR, Olsen RH, Jürs A, et al. A randomised trial comparing weight loss with aerobic exercise in overweight individuals with coronary artery disease: The CUT-IT trial [published online ahead of print July 31, 2014]. Eur J Prev Cardiol. doi: 10.1177/2047487314545280.
51. NHLBI Obesity Education Initiative Working Group. The Practical Guide. Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD: NIH/NHLBI/NAASO; October 2000. NIH Publication 00-4084.
52. FDA 2007 Draft Guidance for Industry. Developing products for weight management. U.S. Department of Health and Human Services, Food and Drug Administration. 2007. http://www.fda.gov/downloads/advisorycommittees/committees meetingmaterials/drugs/endocrinologicandmetabolicdrugs advisorycommittee/ucm299133.pdf/. Accessed April 21, 2014.
53. Rothman RB, Baumann MH, Dersch CM, et al. Amphetaminetype central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001; 39: 32-41.
54. Aronne LJ, Powell AG, Apovian CM. Emerging pharmacotherapy for obesity. Expert Opin Emerg Drugs. 2011; 16: 587-596.
55. O'Meara S, Riemsma R, Shirran L, Mather L, TerRiet G. A systemic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004; 5: 51-68.
56. Padwal RS, Rucker D, Li SK, Curioni C, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003 (4): 1-48.
57. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest. 2003; 111: 565-570.
58. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity. 2013; 21: 2163-2171.
59. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin N Am. 2010; 39: 69-79.
60. Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014; 56: 465-472.
61. Allison DB, Gadde KM, Garvey WT, et al. Controlled-released phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012; 20: 330-342.
62. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377 (9774): 1341-1352.
63. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2011; 95: 297-308.
64. Nichols DE. Hallucinogens. Pharmacol Ther. 2004; 101: 131-181.
65. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000; 57: 75-81.
66. Launay JM, Hervé P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002; 8: 1129-1135.
67. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363: 245-256.
68. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM Trial. J Clin Endocrinol Metab. 2011; 96: 3067-3077.
69. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20: 1426-1436.
70. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. JAMA. 2005; 294: 1960-1963.
71. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004; 89: 2608-2615.
72. Dimitriadis E, Daskalakis M, Kampa M, Peppe A, Papdakis JA, Melissas J. Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study. Ann Surg. 2013; 257: 647-654.
73. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009; 250: 234-241.
74. Dixon JB, Straznicky N, Lambert EA, Schlaich MP, Lambert GW. Laparoscopic adjustable gastric banding and other devices for the management of obesity. Circulation. 2012; 126: 774-785.
75. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systemic review and meta-analysis. JAMA. 2004; 292: 1724-1737.
76. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008; 299: 316-323.
77. Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367: 695-704.
78. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012; 307: 56-65.
79. Nguyen NT, Slone JA, Nguyen X-MR, Hartman JS, Hoyt DB. A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg. 2009; 250: 631-641.
80. Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008; 121: 885-893.
81. Suter M, Calmes JM, Paroz A, Giusti V. A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates. Obes Surg. 2006; 16: 829-883.
82. Dixon JB, LeRoux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet. 2012; 379 (9833): 2300-2311.
83. Gill RS, Birch DW, Shi X, Sharma AM, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010; 6: 707-713.
84. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012; 366: 1567-1576.
85. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014; 370: 1-12.
86. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg. 2011; 254: 410-422.
87. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357: 753-761.
88. Sjöström L, Narbro K, Sjöström D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357: 741-752.
89. Mingrone G, Panunzi S, DeGastano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366: 1577-1585.
90. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013; 309: 2240-2249.